Moderna produced the vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, the institute that is headed by Dr. Anthony Fauci and has been leading the clinical trials. Part of the National Institutes of Health, the agency is involved in research on other experimental coronavirus vaccines. Moderna and Johnson & Johnson have each received roughly half a billion dollars from the U.S. government, to speed development of a vaccine. The potential strength of Moderna’s mRNA approach to vaccine making is that it uses a genetic framework that can be quickly adapted for each new viral threat. The science behind the pipeline Moderna calls mRNA “the software of life.” Cells use mRNA to translate DNA into the proteins the body uses to function. Moderna believes it can use mRNA to spur the body to produce its own therapeutic proteins, essentially putting a drug factory inside of the patient. As one might guess, it’s not an easy task. Moderna’s scientists have a big job ahead of them: For each potential drug, they need to figure out how to safely get the mRNA therapy into the appropriate cells, make sure the mRNA actually yields sufficient amounts of protein to have a therapeutic effect and ensure the therapies won’t trigger an immune reaction in patients. MordenaWho are the major shareholders of Moderna:
1. IPO in 2018 - Valuation: $7.5 B Raised : $604.3 M Moderna sold about 26.3 million shares priced at $23 a share late Thursday, at the midpoint of the projected range of $22 to $24 2. Today on 2020.05.19 $76.28
0 Comments
Leave a Reply. |
Other News
Archives
January 2021
Categories
|